Aaptamine – a dual acetyl – and butyrylcholinesterase inhibitor as potential anti-Alzheimer’s disease agent
Open accessThe DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Abstract
Context Alzheimer’s disease (AD) is a neurodegenerative disorder that affects millions of people worldwide. Acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) are promising therapeutic targets for AD.Objective To evaluate the inhibitory effects of aaptamine on two cholinesterases and investigate the in vivo therapeutic effect on AD in a zebrafish model.Materials and methods Aaptamine was isolated from the sponge Aaptos suberitoides Brøndsted (Suberitidae). Enzyme inhibition, kinetic analysis, surface plasmon resonance (SPR) and molecular docking assays were used to determine its inhibitory effect on AChE and BuChE in vitro. Zebrafish were divided into six groups: control, model, 8 μM donepezil, 5 , 10 and 20 μM aaptamine. After three days of drug treatment, the behaviour assay was performed.Results The IC50 values of aaptamine towards AChE and BuChE were 16.0 and 4.6 μM. And aaptamine directly inhibited the two cholinesterases in the mixed inhibition type, with Ki values of 6.96 ± 0.04 and 6.35 ± 0.02 μM, with Kd values of 87.6 and 10.7 μM. Besides, aaptamine interacts with the crucial anionic sites of AChE and BuChE. In vivo studies indicated that the dyskinesia recovery rates of 5 , 10 and 20 μM aaptamine group were 34.8, 58.8 and 60.0%, respectively, and that of donepezil was 63.7%.Discussion and conclusions Aaptamine showed great potential to exert its anti-AD effects by directly inhibiting the activities of AChE and BuChE. Therefore, this study identified a novel medicinal application of aaptamine and provided a new structural scaffold for the development of anti-AD drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Targeting both AChE and Butyrylcholinesterase (BuChE) not only alleviates cognitive impairment in AD patients by increasing ACh levels but also serves as a disease-modifying agent, delaying the formation of Aβ plaques.527–529”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [527]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ligand docking and binding site analysis with PyMOL and Autodock/Vina
Seeliger, D., & de Groot, B. L. (2010) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-010-9352-6 · Cited by 2,623 · cited 1×
“The molecular simulation diagram is drawn by PyMOL software (Seeliger and de Groot 2010).”
MethodLane, C. A., Hardy, J., & Schott, J. M. (2018) · European Journal of Neurology · doi:10.1111/ene.13439 · Cited by 2,616
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918 · cited 1×
“Many studies have revealed that AChE and BuChE are key players involved in the pathology of AD and may serve as potential therapeutic targets (Hampel et al. 2018).”
BackgroundAlzheimer's disease: Targeting the Cholinergic System
H. Ferreira-Vieira, T., M. Guimaraes, I., R. Silva, F., & M. Ribeiro, F. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666150716165726 · Cited by 1,551 · cited 1×
“The maintenance of acetylcholine (ACh) levels by inhibiting cholinesterase activity has been proven to be a successful way to relieve some cognitive and behavioural symptoms of AD (Ferreira-Vieira et al. 2016).”
BackgroundStructures of Human Acetylcholinesterase in Complex with Pharmacologically Important Ligands
Cheung, J., Rudolph, M. J., Burshteyn, F., Cassidy, M. S., Gary, E. N., Love, J., Franklin, M. C., & Height, J. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300871x · Cited by 1,356 · cited 3×
“Crystal structures of recombinant human AChE in complex with Donepezil (4EY7) and BuChE with N-[1-(2,3-dihydro-1H-inden-2-yl)piperidin-3yl)methyl]-N-(2-(dimethylamino)ethyl)-2-naphthamide (4TPK) were obtained from the Protein databank (Cheung et al. 2012; Brus et al. 2014; Sakayanathan et al. 2019).”
BackgroundMethodInfluentialCurrent understanding of Alzheimer’s disease diagnosis and treatment
Weller, J., & Budson, A. (2018) · F1000Research · doi:10.12688/f1000research.14506.1 · Cited by 1,083 · cited 1×
“Cholinergic deficits resulting in the loss of brain-cell communication are the most popular hypothesis (Weller and Budson 2018).”
BackgroundA review on cholinesterase inhibitors for Alzheimer’s disease
Anand, P., & Singh, B. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0036-3 · Cited by 709 · cited 1×
“Although new cholinesterase inhibitors, including naturally occurring or synthesized compounds, have been reported, of which only a small number are dual AChE-BuChE inhibitors (Anand and Singh 2013; Li et al. 2017; Moodie et al. 2019).”
BackgroundLi, Q., Yang, H., Chen, Y., & Sun, H. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.062 · Cited by 322 · cited 1×
“Although new cholinesterase inhibitors, including naturally occurring or synthesized compounds, have been reported, of which only a small number are dual AChE-BuChE inhibitors (Anand and Singh 2013; Li et al. 2017; Moodie et al. 2019).”
BackgroundSelf-citationDhillon, S. (2021) · Drugs · doi:10.1007/s40265-021-01569-z · Cited by 293 · cited 2×
“market in 1998 due to hepatotoxicity (Dhillon 2021).”
BackgroundBrus, B., Košak, U., Turk, S., Pišlar, A., Coquelle, N., Kos, J., Stojan, J., Colletier, J.-P., & Gobec, S. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501195e · Cited by 285
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“526 527 – 529 The dual inhibitor of AChE and BuChE, compound 45 , signi fi cantly enhanced the learning and memory abilities of aged AD mice.”
BackgroundCarroll, A. R., Copp, B. R., Grkovic, T., Keyzers, R. A., & Prinsep, M. R. (2024) · Natural Product Reports · doi:10.1039/d3np00061c · Cited by 171
The mechanisms, hallmarks, and therapies for brain aging and age-related dementia
Jin, S., Lü, W., Zhang, J., Zhang, L., Tao, F., Zhang, Y., Hu, X., & Liu, Q. (2024) · 中国科学通报:英文版 · doi:10.1016/j.scib.2024.09.005 · Cited by 44
Marine Natural Products in Inflammation‐Related Diseases: Opportunities and Challenges
Zhang, T., Ouyang, Z., Zhang, Y., Sun, H., Kong, L., Xu, Q., Qu, J., & Sun, Y. (2025) · Medicinal Research Reviews · doi:10.1002/med.22109 · Cited by 23
“Researchers have discovered that aaptamine exhibits strong potential in combating Alzheimer's disease (AD) by inhibiting acetylcholinesterase and butyrylcholinesterase [95].”
Pidaný, F., Křoustková, J., Mamun, A. A., Suchánková, D., Brazzolotto, X., Nachon, F., Chantegreil, F., Doležal, R., Pulkrabkova, L., Múčková, Ľ., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115301 · Cited by 21
Metadata
- Authors
- Miao, S., He, Q., Li, C., Wu, Y., Liu, M., Chen, Y., Qi, S., & Gong, K.
- Affiliations
- Binzhou Medical University (CN)
- Wuhan Institute of Technology (CN)
- Corresponding author
- Qi, Shizhou
- Gong, Kaikai
- Venue
- Pharmaceutical Biology
- Publisher
- Informa UK Limited
- Published
- 2022-08-14
- Volume
- 60
- Issue
- 1
- Pages
- 1502-1510
- ISSN
- 0925-1618 (ISSN-L)
- 1388-0209
- 1744-5116
- PMC
- PMC9380430
- OpenAlex
- W4291471200
- Cited by
- 29
- References
- 48
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 10 · 2023: 4
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutical Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81903537, 31900441, 81903102)
- Natural Science Foundation of Shandong Province (ZR2018BB024)
- Traditional Chinese Medicine Technology Development Foundation of Shandong (2019-0521)
- Science and Technology Development Foundation of Binzhou (2015ZC0304)
- Research Foundation of Binzhou Medical University (BY2015KYQD31, BY2017KJ17)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Keywords
- aaptamine, Alzheimer's disease, acetylcholinesterase inhibition, butyrylcholinesterase inhibition, dual cholinesterase inhibitors, marine sponge natural products, zebrafish model, donepezil, mixed-type inhibition, enzyme kinetics, anti-Alzheimer drug candidates
- MeSH terms
- Donepezil, Acetylcholinesterase, Alzheimer Disease, Animals, Butyrylcholinesterase, Cholinesterase Inhibitors, Humans, Kinetics, Naphthyridines, Zebrafish, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aaptamine – a dual acetyl – and butyrylcholinesterase inhibitor as potential anti-Alzheimer’s disease agent. https://app.cochat.ai/papers/10.1080/13880209.2022.2102657
- The paper
- Miao, S., He, Q., Li, C., Wu, Y., Liu, M., Chen, Y., Qi, S., & Gong, K. (2022). Aaptamine – a dual acetyl – and butyrylcholinesterase inhibitor as potential anti-Alzheimer’s disease agent. Pharmaceutical Biology. https://doi.org/10.1080/13880209.2022.2102657
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.